The influence of metabolic syndrome in the outcomes of colorectal cancer patients

Goulart, A; Varejão, A; Nogueira, F; Martins, S; Mesquita-Rodrigues, A; Sousa, N; Leão, P

http://hdl.handle.net/10400.23/1196

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
Diabetes Metab Syndr. 2017.pdf		239.72 KB	Adobe PDF	Download

Send Feedback

Authors

Mesquita-Rodrigues, A

Sousa, N

Leão, P

Abstract(s)

AIMS: Determine the influence of metabolic syndrome and its different components in the outcomes of colorectal cancer surgery at 30days. MATERIALS AND METHODS: Prospective study that included all patients submitted to elective colorectal cancer surgery between August 2015 and August 2016 at Hospital de Braga. Clinical and laboratory parameters evaluated pre-operatively were: central obesity, blood pressure, fasting glucose, triglycerides levels and HDL cholesterol levels. Any complications during the first 30-days after surgery were recorded (readmission, reintervention, anastomotic dehiscence, morbimortality). RESULTS: One hundred and thirty-four patients were included. Metabolic syndrome was diagnostic in 40.7% of patients with the ATPIII definition, 67.5% with the AHA definition and 67.0% with the IDF definition. At 30days after colorectal cancer surgery, 73.1% patients don't have any complication, 15.7% have minor complications (grade I/II of Clavien-Dindo classification), 11.1% have major complications (grade III/IV/V of Clavien-Dindo classification) and 1.5% have died from surgical complications (grade V of Clavien-Dindo classification). The statistic analysis didn't reveal any association between MS, or it's different components, and surgical outcomes. CONCLUSION: This study seems to indicate that metabolic syndrome don't have any influence in surgical outcomes of colorectal cancer surgery.